Jiangsu Key Laboratory of Oral Diseases, Department of Prosthodontics, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing 210029, People's Republic of China.
Int J Nanomedicine. 2020 Jan 23;15:497-511. doi: 10.2147/IJN.S228797. eCollection 2020.
RNA-based therapy for bone repair and regeneration is a highly safe and effective approach, which has been extensively investigated in recent years. However, the molecular stability of RNA agents still remains insufficient for clinical application. High porosity, tunable size, and ideal biodegradability and biosafety are a few of the characters of mesoporous silicon nanoparticles (MSNs) that render them a promising biomaterial carrier for RNA treatment.
In this study, a novel miR-26a delivery system was constructed based on MSNs. Next, we assessed the miRNA protection of the delivery vehicles. Then, rat bone marrow mesenchymal stem cells (rBMSCs) were incubated with the vectors, and the transfection efficiency, cellular uptake, and effects on cell viability and osteogenic differentiation were evaluated.
The results demonstrated that the vectors protected miR-26a from degradation in vitro and delivered it into the cytoplasm. A relatively low concentration of the delivery systems significantly increased osteogenic differentiation of rBMSCs.
The vectors constructed in our study provide new methods and strategies for the delivery of microRNAs in bone tissue engineering.
基于 RNA 的骨修复和再生治疗是一种高度安全有效的方法，近年来得到了广泛的研究。然而，RNA 制剂的分子稳定性仍然不足以满足临床应用的要求。高孔隙率、可调尺寸以及理想的生物降解性和生物安全性是介孔硅纳米粒子（MSNs）的一些特点，使其成为 RNA 治疗的一种有前途的生物材料载体。
本研究构建了基于 MSNs 的新型 miR-26a 递药系统。接下来，我们评估了递药载体对 miRNA 的保护作用。然后，将大鼠骨髓间充质干细胞（rBMSCs）与载体孵育，评估转染效率、细胞摄取以及对细胞活力和成骨分化的影响。
结果表明，载体可在体外保护 miR-26a 不被降解，并将其递送至细胞质。相对较低浓度的递药系统可显著促进 rBMSCs 的成骨分化。
本研究构建的载体为骨组织工程中 miRNA 的递呈提供了新的方法和策略。
